In ESCC patients with definitive chemoradiotherapy (dCRT), those with high expression of SLFN11(H-score ≥ 51 was defined as high SLFN11 expression) exhibited significantly better prognosis (p = 0.013), particularly notable in stage II and III patients (p = 0.004) (36). The gene discussed is SLFN11; the disease is esophageal squamous cell carcinoma.